News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Opportunistic infections news

Show

From To
Opportunistic infections
Gilead fails to keep promise on access to lifesaving drug for people living with HIV

Pharmaceutical corporation Gilead promised to expand access at an affordable price to a drug for people with an HIV-related infection, cryptococcal meningitis. One year on, the drug is registered in only six developing countries and remains prohibitively expensive.

Published
01 July 2019
From
Médecins Sans Frontières
Opportunistic infections
A considerable percentage of deaths in HIV patients are due to cryptococcal infections

Cryptococcal meningitis causes about one in ten HIV-related deaths, according to a study of autopsies performed in Mozambique and Brazil.

Published
22 May 2019
From
Eurekalert Inf Dis
Opportunistic infections
A Mysterious Infection, Spanning the Globe in a Climate of Secrecy

The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in India, Pakistan and South Africa.

Published
08 April 2019
From
New York Times
Opportunistic infections
Study: AIDS-immunocompromised populations see more antibiotic-resistant infections

Populations with a high prevalence of AIDS-immunocompromised people are more likely to see the emergence of antibiotic-resistant bacterial infections, according to a study coauthored by researchers at the University of Tennessee, Knoxville, and published in PLOS One.

Published
27 March 2019
From
Eurekalert Inf Dis
Opportunistic infections
Back to the future with CD4 testing: Improving HIV care in low- and middle-income countries

A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.

Published
16 January 2019
From
Science Daily
Opportunistic infections
HIV-Positive Patients at Higher Risk of Late Mortality Following Cryptococcal Infection

New research being presented in a Poster Abstract Session at ID Week 2018, suggests that patients living with HIV have high mortality following cryptococcal infection which persists beyond initial hospitalization. As such, the investigators stress the need to identify patients who are at increased risk of mortality in order to improve patient outcomes.

Published
04 October 2018
From
Contagionlive.com
Opportunistic infections
Uganda: No More Septrin for Aids Patients - Government

People living with HIV/Aids in Uganda (PLWHA) will stop taking Septrin as a complementary drug that fights opportunistic infections such as malaria, diarrhoea and pneumonia, according to the new Health ministry guidelines.

Published
04 September 2018
From
AllAfrica
Access to medicines and treatment
Price cut on medicine will help preserve the health of more people living with HIV

Unitaid and Indian drug manufacturer Cipla Ltd. struck a landmark agreement today that will lower the price of the first combination therapy (containing co-trimoxazole, isoniazid and vitamin B6) that prevents opportunistic infections in people living with HIV.

Published
11 June 2018
From
UNITAID
Opportunistic infections
Integrase inhibitors do not raise risk of IRIS in severely immunocompromised people

Use of an integrase inhibitor, which can bring down viral load rapidly, was not associated with an increased risk of immune reconstitution inflammatory syndrome (IRIS) in people

Published
27 March 2018
By
Liz Highleyman
Opportunistic infections
Raltegravir-Intensified ART: More Rapid Declines in HIV Viral Load But No Impact On IRIS

At the 25th Conference on Retroviruses and Opportunistic Infections (CROI) Diana Gibb, MD, professor of epidemiology, program leader of the Pediatric Program of trials and cohorts at the Medical Research Council Clinical Trials Unit at UCL, London, shared results from a REALITY trial (ISRCTN43622374) which explored the impact of raltegravir intensification of first-line antiretroviral therapy (ART) on immune reconstitution inflammatory syndrome (IRIS).

Published
13 March 2018
From
Contagion Live
← First12345...13Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.